DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/trx4pw/alcohol_addiction) has announced the addition of the "Alcohol Addiction - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
- The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Alcohol Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
-
A review of the Alcohol Addiction products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
Companies Involved:
- AbbVie Inc.
- Addex Therapeutics
- Adial Pharmaceuticals, LLC
- AllTranz, Inc.
- Bionex Pharmaceuticals LLC
- Curemark, LLC
- D&A Pharma SAS
- Eli Lilly and Company
- Euthymics Bioscience, Inc.
- Heptares Therapeutics Ltd.
- Johnson & Johnson
- Kyorin Pharmaceutical Co., Ltd.
- Omeros Corporation
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Tekmira Pharmaceuticals Corp.
-
VM Discovery, Inc.
Drug Profiles:
- baclofen
- ibudilast
- aprepitant
- ABT-436
- pioglitazone hydrochloride
- OMS-403
- LY-2940094
- (topiramate + ondansetron)
- ondansetron
- sodium oxybate IR
- OMS-405
- GET-73
- ivermectin
- oxytocin
- baclofen ER
- JNJ-39220675
- amitifadine
- ADX-71441
- OMS-527
- TKM-ALDH2
- Small Molecule Targeting Orexin 1
- CM-1212
- JNJ-31020028
- SLV-330
- Drugs to Inhibit Histone Deacetylase for CNS Disorders
- JNJ-5234801
- VMD-2202
- Drug For Alcohol Addiction
- Compound 1
- Small Molecule To Antagonize Ghrelin For Alcoholism
For more information visit http://www.researchandmarkets.com/research/trx4pw/alcohol_addiction
